As per estimations by one of its lenders in February 2009, Ranbaxy Laboratories may be sitting on mark-to-market (MTM) losses of more than Rs 25 billion on foreign currency derivatives transactions signed up with a range of banking institutions.

With this lender alone, Ranbaxy is suffering an MTM loss of Rs 6 billion on the derivatives contracts that it signed during April-May 2008.

But, Ranbaxy is not the only company that has been hit by forex derivatives losses. The losses have seen across the segments.

Following the report, shares of the company lost 4.7% to trade at Rs 190.50 at 12:38 p.m. The total volume of shares traded was 658,225 at the BSE.

Current EPS & P/E ratio stood at 0.57 and 334.19 respectively. The share price has seen a 52-week high of Rs 612.75 and a low of Rs 133.15 on BSE.